Tag: SAINT
Magnus highlights new SAINT clinical data at 2024 NYC Neuromodulation Conference
Magnus Medical has announced promising new clinical data on its Stanford accelerated intelligent neuromodulation therapy (SAINT) at the 2024 NYC Neuromodulation Conference (31 July–4...
MagVenture and Magnus to collaborate on bringing SAINT neuromodulation system to...
MagVenture has announced a partnership with Magnus Medical that is intended to provide its industry-leading MagPro magnetic stimulation system to support an “exciting new chapter”...
Magnus announces first treatments in OLO clinical trial of novel depression...
Magnus Medical has announced that the first participants have been treated in the Open Label Optimisation (OLO) clinical trial evaluating the effectiveness of the...
Magnus shares study results indicating SAINT depression treatment changes abnormal brain...
Magnus Medical has shared promising results from a clinical trial published in the Proceedings of the National Academy of Sciences indicating that treatment with SAINT neuromodulation...
Magnus receives US FDA clearance for SAINT neuromodulation system in severe...
Magnus Medical has announced receipt of 510(k) clearance from the US Food and Drug Administration (FDA) for its SAINT neuromodulation system for the treatment of...
Novel neuromodulation technique could be “gamechanger” in treatment-resistant depression
Stanford accelerated intelligent neuromodulation therapy (SAINT)—a novel, high-dose intermittent theta-burst stimulation (iTBS)—was found to be safe and more effective than sham stimulation in a...
